zelenectide pevedotin — Initial data
H2 2026
Initial data for Phase 1/2 Duravelo-3 trial exploring zelenectide pevedotin in NECTIN4 amplified breast cancer expected in the second half of 2026Source filing
BCYC biotech catalysts & pipeline
BICYCLE THERAPEUTICS PLC · Data as of 2026-09-08